Peptide YY is a key satiety hormone released from the gut after eating. It plays a central role in the “gut-brain axis” that controls appetite. Research interest centers on its potential as a therapeutic target for obesity, either through direct administration or by enhancing endogenous PYY release through dietary interventions.
Dosage Information (Research Use)
Research doses: IV infusion at 0.8 pmol/kg/min in clinical studies. No standardized subcutaneous dosing established. Research compound only.
Reconstitution & Handling
Reconstitute with sterile water per manufacturer instructions.
Half-Life & Pharmacokinetics
~10-30 minutes
Reported Observations in Literature
Nausea at higher doses, transient increase in heart rate, abdominal discomfort. Generally well-tolerated in research settings at physiological doses.
Key Research References
- Batterham RL et al. “Gut hormone PYY3-36 physiologically inhibits food intake.” Nature. 2002;418:650-4